News | September 19, 2013

JenaValve TAVI System Receives Extended CE Mark Approval

System Unique in Treatment Of Aortic Insufficiency

JenaValve, TAVI system, heart valve repair, CE Mark, JenaValve CE Mark

JenaValve transapical TAVI system

September 19, 2013 – JenaValve Technology Inc. has received CE (Conformite Europeenne) mark approval from European regulators for its transapical TAVI system for the treatment of aortic insufficiency (AI), also known as aortic regurgitation, in which the native aortic valve does not close properly and allows blood to leak back into the left ventricle of the heart.

The JenaValve is now the only TAVI device worldwide approved for the treatment of high-risk or inoperable patients suffering from severe aortic insufficiency. The CE mark expansion, which is an addition to JenaValve's initial September 2011 CE mark approval for the treatment of stenosed and calcified aortic valve diseases, enables JenaValve to market its product for AI to physicians and their patients throughout all countries recognizing the CE mark. The JenaValve is now approved for the entire range of aortic valve disease — from severely calcified to not calcified at all.

JenaValve CEO Helmut J. Straubinger said, "The granting of a CE mark expansion to cover the clinical indication of aortic insufficiency is testament to the unique design of our valve and will provide a new option for thousands of patients; more than 23 percent of all patients with native aortic valve diseases suffer from AI. Today, open-heart valve replacement surgery is the standard procedure for AI patients; high-risk patients or inoperable patients are treated conservatively with drugs. According to published clinical data, the yearly mortality rate of these conservatively treated patients is approximately 25 percent. For these patients, the JenaValve now provides a beneficial alternative treatment opportunity."

JenaValve's competitive advantage for AI is attributable to its patented clip-mechanism that allows for "active fixation" on the diseased valve leaflets and requires no calcification of the native valve to be implanted and effective. The JenaValve TAVI system is clipped and fixed on the native valve leaflets in a manner similar to a paper clip. Other competing TAVI products are not suitable for AI because they require a certain amount of calcification in order to properly position and secure their valve prosthesis. Without calcification, there is significant risk that these other devices will migrate into the aortic arch causing risk to the patient. Clinical studies performed with competitor devices in patients with pure AI revealed unsatisfying results with a high number of residual paravalvular leaks requiring second interventions. [1]

Hendrik Treede, M.D., director of minimally invasive cardiac surgery at the University Heart Center Hamburg, said, "Severe aortic regurgitation is an indication for surgical aortic valve repair or replacement in the majority of patients. Nevertheless there is a need for interventional catheter based aortic valve implantation in patients at high surgical risk or with contraindications for surgery. First-generation TAVI devices require substantial oversizing in non-calcified annuli carrying the risk of paravalvular leakage, valve migration or further annulus dilatation. The JenaValve TAVI system has proven safety and efficacy in catheter-based treatment of pure aortic regurgitation in sufficient numbers of patients."

For more information:

1. Roy DA, Schaefer U, Guetta V, Hildick-Smith D, Möllmann H, Dumonteil N, Modine T, Bosmans J, Petronio AS, Moat N, Linke A, Moris C, Champagnac D, Parma R, Ochala A, Medvedofsky D, Patterson T, Woitek F, Jahangiri M, Laborde JC, Brecker SJ. Transcatheter Aortic Valve Implantation for Pure Severe Native Aortic Valve Regurgitation. J Am Coll Cardiol. 2013 Feb 14

Related Content

Videos | Heart Valve Technology | March 15, 2018
Insights from the STS/ACC TVT Transcatheter Valve Registry, presented at the American College of Cardiology (ACC) 201
CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials
News | Heart Valve Technology | March 12, 2018
Medtronic plc unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (...
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used in newborn pediatric patients to treat heart defects.
News | Heart Valve Technology | March 07, 2018
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used...
Videos | Heart Valve Technology | March 02, 2018
Sammy Elmariah, M.D., MPH, interventional structural heart disease, Massachusetts General Hospital, discusses the pro
Boston Scientific Projects 2019 Launch for Lotus Edge Aortic Valve System
News | Heart Valve Technology | February 23, 2018
February 23, 2018 — Boston Scientific announced In November 2017 a delay to timelines for commercialization of the Lo
Gate Bioprosthesis Used in Canada's First Transcatheter Valve Replacement for Tricuspid Regurgitation
News | Heart Valve Technology | February 22, 2018
NaviGate Cardiac Structures Inc. (NCSI)announced that on Feb. 2, 2018, its catheter-guided Gate valved-stent...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Overlay Init